SHR-A1811
DrugSHR-A1811
NCT Number: NCT06710990
The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SHR-A1811
Ritonavir
Itraconazole
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time frame: From the beginning of screening period to approximately 3 months after the last dose.
Jiangsu HengRui Medicine Co., Ltd.
Industry
A Multicenter, Open-label, Fixed-sequence Study to Evaluate Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05631795
Advanced Breast Cancer, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Guwahati, Assam, India
View Trial DetailsNCT07178743
Advanced Breast Cancer
Boston, Massachusetts, United States
View Trial DetailsNCT07225790
Advanced Breast Cancer
Boston, Massachusetts, United States
View Trial DetailsNCT07274709
Advanced Breast Cancer
Boston, Massachusetts, United States
View Trial Details